ADBE SHORTADBE looks like a good short here with a bounce off the fib. It has a nice tight stop-loss. Also huge risk/reward
Trading JournalUI was leading as market was showing signs of weakness by going sideways. Brokeout just before market turned around and made all time high.
Reason for selling, stalling action, plus need to reduce exposure and make room for other trades.
Could be last breakout as stock has gone continuously up from $100x to $400 and didn't even close below 21 ema
WULF LONGWe are currently in spring, from here or we go up above 9.2 or we go lower.
my analyze is based on Wyckoff accumulation structure.
Based on that my SL will be 5.7$ last support on 1D chart, wish i think if it goes below it we should go lower than 5$
Target would be 10.8, the trade would take time
great risk/reward ratio
$TDOC sling shot to $35-50 | 400-500% return- Fundamentals are improving, people shorted it because they thought pandemic boosts virtual care but there will always be demand for virtual care & reference when it comes to getting medicine.
- There's huge shortage of doctors and wait times at hospital is awful.
- This stock is getting accumulated by whales. I believe longer the base, higher in space.
PT 1: 35
PT 2: 50
CAG to $27My trading plan is very simple.
I buy or sell when price tags the top or bottom of parallel channels.
I confirm when price hits Fibonacci levels.
So...
Here's why I'm picking this symbol to do the thing.
Price at bottom of channels (period 52 39 & 26)
Stochastic Momentum Index (SMI) at oversold level
VBSM is spiked negative and below Bollinger Band
Entry at $25.50
Target is $27 or channel top
Today TSLA analysis.hello'
"TSLA's downtrend was evident today, and by using the RSI indicator, I identified a clear target. I hope the prediction proves accurate. Additionally, given TSLA's all-time high, it's possible we'll see a pullback to recover some of those gains."
Target
1: 400.00
2: 370.00
I hope you like my target. what you think about ''TSLA'' ?
SJM to $110My trading plan is very simple.
I buy or sell when price tags the top or bottom of parallel channels.
I confirm when price hits Fibonacci levels.
So...
Here's why I'm picking this symbol to do the thing.
Price at bottom of channels (period 100 52 39 & 26)
Stochastic Momentum Index (SMI) at oversold level
VBSM is spiked negative and below Bollinger Band
Entry at $104.75
Target is $110 or channel top
Energy Fuels Stock: Potential Reversal Ahead?AMEX:UUUU
After reaching a low of $0.78 in March 2020, AMEX:UUUU has been on a recovery path. Currently, it's forming an inverted head and shoulders pattern, with the key neckline at $7.47. A breakout above this level could signal a move towards $9.73.
However, watch out for the bearish alt-bat pattern near $9.73, which could lead to a pullback. Stay alert for key price action and adjust your risk accordingly.
⚠️ Note: Any violation of the $4.19 support would invalidate the projected patterns in this idea.
SHAK to $125My trading plan is very simple.
I buy or sell when price tags the top or bottom of parallel channels.
I confirm when price hits Fibonacci levels.
So...
Here's why I'm picking this symbol to do the thing.
Price below bottom channels (period 100 52 39 & 26)
Stochastic Momentum Index (SMI) at oversold level
VBSM is spiked negative and below Bollinger Band
Entry at $116.45
Target is $125 or channel top
Tesla possible projections for earnings. Simple - Based on Fib Levels - A straddle or strangle at 579$ and 395$ could earn good money.
LNG - Favorite stock in the entire nat gas space.The fundamentals are in place for LNG to double. LNG is the premier Liquefied Natural Gas play in the space.
I sold at $236 thinking that was all it could do. I was wrong and it continues to make new highs. The RSI on the daily right now is 87.67. We should get a pullback here somewhere to try this ride up again.
Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1996 and is headquartered in Houston, TX.
This is not investment advice, I'm just a village idiot that likes to think out loud.
SHORT ORCLOracle Corporation (ORCL) has recently experienced a decline due to underwhelming earnings and concerns over its valuation.
The stock is currently trading at $183.47. Given the elevated implied volatility in the options market, a short call strategy may be more cost-effective than purchasing puts.
Trade Plan Details
1. Short Call Strategy:
Strike Price: $190 (above current trading price)
Expiration: March 2025
Premium: Collect premium by selling call options at this strike.
2. Position Sizing:
Contracts: Determine the number of contracts based on your risk tolerance and account size.
Risk Management: Ensure the total potential loss does not exceed your predefined risk threshold.
3. Profit Target:
Objective: Profit from the premium received, anticipating that ORCL will stay below the $190 strike price by expiration.
4. Stop Loss:
Exit Strategy: If ORCL's price approaches the strike price, consider closing the position to limit potential losses.
Rationale
Earnings Performance: Oracle's recent earnings report showed revenue of $14.06 billion, slightly below expectations, leading to a stock decline.
Valuation Concerns: Analysts have downgraded Oracle due to overvaluation concerns, suggesting the stock may face further downward pressure.
Implied Volatility: Elevated implied volatility makes selling options, such as short calls, potentially more profitable due to higher premiums.
PUT sale on SHAKSHAK has retraced over 10%, 4 bearish candles in a row plus its hitting the daily 100SMA.. a rebound is over due. Getting over 1% premium and expiration is not too far from today.
Phathom Pharmaceuticals: Biopharmaceutical Stock (300%)I spend time researching and finding the best entries and setups, so make sure to boost and follow for more.
Phathom Pharmaceuticals ( NASDAQ:PHAT ): Biopharmaceutical Stock with High Upside Potential
Trade Setup:
- Entry Price: $6.92
- Stop-Loss: $5.82
- Take-Profit Targets:
- TP1: $19.69
- TP2: $31.39
Company Overview:
Phathom Pharmaceuticals ( NASDAQ:PHAT ) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. Their flagship product, vonoprazan, is poised to disrupt the market with its innovative approach to acid-related conditions.
Market Sentiment:
The recent FDA approval has significantly improved market sentiment, with increased trading volumes and positive investor outlook. Phathom's focus on a high-demand therapeutic area further supports long-term bullish prospects.
Risk Management:
A stop-loss at $5.82 limits downside risk, while the take-profit targets offer exceptional upside potential. TP1 represents a **179% gain**, and TP2 offers a massive **346% return**, making this trade setup attractive for swing and long-term investors.
When the Market’s Call, We Stand Tall. Bull or Bear, We’ll Brave It All!
*Disclaimer: This analysis is for informational purposes only and does not constitute financial advice. Traders should conduct their own due diligence before making investment decisions.*
H5_L Screener Run Through! 22Jan2025In this video, I run through my H5_L Screener!
Todays date: 22Jan2025
Found some great trades and setups using my screener!
Not financial advice
